Back to Market Feed

Product Information

GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $3203.2840 per ML under NDC 72065012012. Its NADAC has been published 253 times since Oct 20, 2021.

FDA first approved this application on Sep 10, 2019.

GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML

glucagon injection, solution
$3203.2840per ML

Strength

.5 mg/.1mL

NDC

72065012012

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

FDA Approved

9/10/2019

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML has been published 253 times since Oct 20, 2021, and over the history we have for it it has risen 15.6%. The table below summarizes its recorded NADAC range and movement.

Current price$3203.2840 per ML
All-time high$3206.1647 (Aug 12, 2026)
All-time low$2770.4465 (Oct 20, 2021)
52-week high$3206.1647
52-week low$3109.1217
Median price$3024.4585
Average price$2994.9829
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked253
Tracking sinceOct 20, 2021

Price History

1W

-0.1%

1M

-0.1%

3M

-0.1%

6M

-0.1%

1Y

+3.0%

3Y

+9.0%

5Y

N/A

All

+15.6%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the glucagon injection, solution market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

BAQSIMI 3 MG SPRAY ONE PACK
Brand
00548835101•Amphastar Pharmaceuticals, Inc.
$293.3876
per EA
BAQSIMI 3 MG SPRAY TWO PACK
Brand
00548835202•Amphastar Pharmaceuticals, Inc.
$293.8325
per EA
ZEGALOGUE 0.6 MG/0.6 ML AUTOINJ
Brand
00169191202•Novo Nordisk
$492.8315
per ML
ZEGALOGUE 0.6 MG/0.6 ML AUTOINJ
Brand
00169191201•Novo Nordisk
$493.8960
per ML
ZEGALOGUE 0.6 MG/0.6 ML SYRING
Brand
00169191301•Novo Nordisk
$494.0521
per ML
ZEGALOGUE 0.6 MG/0.6 ML SYRING
Brand
00169191302•Novo Nordisk
$495.0225
per ML
ZEGALOGUE 0.6 MG/0.6 ML AUTOINJ
Brand
80644001201•Zealand Pharma US, Inc
$496.0056
per ML

Frequently asked questions

What is the NADAC price of GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML, manufactured by Xeris Pharmaceuticals, Inc., is $3203.2840 per ML (NDC 72065012012), effective Aug 19, 2026.

How has the price of GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML changed over time?

Over the history we have for it, the NADAC for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML has risen 15.6%. It has been tracked across 253 weekly CMS publications since Oct 20, 2021.

What are the highest and lowest recorded NADAC prices for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML?

Since Oct 20, 2021, the NADAC for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML has ranged from a low of $2770.4465 (Oct 20, 2021) to a high of $3206.1647 (Aug 12, 2026), with a median of $3024.4585 per ML.

Are there cheaper alternatives to GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML?

No other NADAC-published product currently shares the active ingredient and strength of GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML?

GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML (NDC 72065012012) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.